A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers

BACKGROUND: Endogenous serine protease inhibitors are associated with anti-inflammatory and pro-survival signaling mediated via Low-density lipoprotein receptor-related protein 1 (LRP1) signaling. SP16 is a short polypeptide that mimics the LRP1 binding portion of alpha-1 antitrypsin. METHODS: A pil...

Descripción completa

Detalles Bibliográficos
Autores principales: Wohlford, George F., Buckley, Leo F., Kadariya, Dinesh, Park, Taeshik, Chiabrando, Juan Guido, Carbone, Salvatore, Mihalick, Virginia, Halquist, Matthew S., Pearcy, Adam, Austin, Dana, Gelber, Cohava, Abbate, Antonio, Van Tassell, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101931/
https://www.ncbi.nlm.nih.gov/pubmed/33956804
http://dx.doi.org/10.1371/journal.pone.0247357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101931/
https://www.ncbi.nlm.nih.gov/pubmed/33956804
http://dx.doi.org/10.1371/journal.pone.0247357

Ejemplares similares